WHO seeks more data from Sputnik V makers

Anticipated date will be set once all data is submitted and follow-up of inspection observations completed

Picture: Pixabay

Last Updated on September 14, 2021 by The Health Master

The World Health Organisation (WHO) has sought some more data from Russia’s Gamaleya National Research Institute of Epidemiology and Microbiology, developer of C-19 vaccine Sputnik V for according Emergency Use Listing status for the jab.

Sputnik V is currently manufactured in India and being sold by Dr Reddy’s Laboratories under Emergency Use Authorisation route.

According to WHO website, though several meetings were held as part of the process for EUL, the status of assessment column says “On hold, awaiting completion of rolling submission”.

“Anticipated date will be set once all data is submitted and follow-up of inspection observations completed,” WHO said on the decision date for EUL.

Back home, Panacea Biotec supplied the first shipment of the second component of the Russian Sputnik V vaccine manufactured by it for sale in India on September 7.

This is the first batch of the second component produced and supplied by the company in India, the drug firm and the Russian Direct Investment Fund (RDIF) had said in a joint statement.

RDIF has tied up with six Indian drug makers to manufacture Sputnik V and their supplies are expected to roll out by August or September, as senior official of Dr Reddy’s had said earlier.

The global health body is currently reviewing Bharat Biotech’s application for an Emergency Use Listing of its C-19 vaccine Covaxin.



Sputnik V

Steroids: Regulation requited for its dose and duration: Experts

BIS releases updated list of Standards for 4 Equipments

NABL clarifies that it has no Regulatory Powers

UK approves Pfizer, AstraZeneca as Booster dose for Covid

DCGI directs API manufacturers to submit applications online

Latest Notifications regarding Pharmaceuticals


Enter your email address:

Delivered by FeedBurner